Blog
48 Articles
No Time for Self-Pity
When David Smith started losing weight after a diabetes diagnosis, his daughter-in-law was concerned because she had seen this before.
A New Combination Targeting the RAS Pathway
Researchers are testing two new drugs that target the RAS pathway, to make standard chemotherapy more effective.
Don’t Let Doctors Tell You Nothing’s Wrong
After a long road to diagnosis Brandon Stone learned he has a BRCA2 genetic mutation that impacts his treatment.
Pancreatic Cancer Research Updates from ASCO 2024
Learn about the latest developments in pancreatic cancer research into immunotherapy and chemotherapy from the ASCO 2024 meeting.
Study Reveals Molecular Differences in Young-Onset Pancreatic Cancer
There has been a notable increase in cases of young onset pancreatic cancer. Dr. Jashodeep Datta and team are exploring why this is happening.
New Vaccine Harnesses Power Of the Lymph Nodes
A promising new vaccine targets KRAS, the most common mutation in pancreatic cancer. Dr. Shubham Pant provides an update.
ASCO GI Symposium Features a Broad Range of Pancreatic Cancer Research
Researchers at ASCO GI 2024 reported on research in health disparities, KRAS and other genetic mutations, and novel treatments.
Progress and Promise—Research in 2023
What advances were made in 2023 for pancreatic cancer treatments? Where is research headed in the coming year?
Two-Drug Combo Targets KRAS and Fights Resistance
Researcher Hervé Tiriac leads a clinical trial for a new drug combination targeting KRAS and chemotherapy resistance.
Pancreatic Cancer Research Builds Upon Strengths
The September 2023 AACR Special Conference on Pancreatic Cancer focused on the latest research in KRAS, chemotherapy, and cachexia, among other topics.
“Radical Collaboration” to Find Cures for the Deadliest Cancers
Break Through Cancer was founded to promote collaboration between major research institutions, in order to develop cures for the deadliest cancers.
ASCO 2023: Pancreatic Cancer Research Update
The pancreatic cancer research reports from ASCO 2023 focused on different chemotherapy combinations, including immunotherapy.
Research and Other Highlights from the 2023 AACR Annual Meeting
The 2023 AACR meeting focused on the latest research into KRAS, other immunotherapy approaches, and honored Dr. Elizabeth Jaffee.
Newly Discovered Protein Complex in RAS Pathway May Provide a Treatment Target
Dr. Andrew Aguirre and other researchers from Dana-Farber and the Broad Institute are looking at the RAS pathway for a new target.
Report Highlights Potential of TCR Therapy
Read about the potential of TCR therapy, a technique used with success for one pancreatic cancer patient in a groundbreaking immunotherapy clinical trial.